Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu
Trial record 1 of 1 for:    NCT02587416
Previous Study | Return to List | Next Study

Effect of Gemcabene on the Pharmacokinetics of Atorvastatin in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02587416
Recruitment Status : Completed
First Posted : October 27, 2015
Last Update Posted : October 27, 2015
Information provided by (Responsible Party):
Gemphire Therapeutics, Inc.

Brief Summary:
The purpose of this study is to determine the effect of gemcabene on the pharmacokinetics of atorvastatin 80 mg

Condition or disease Intervention/treatment Phase
Hypercholesteremia Drug: Gemcabene 300 mg Drug: Gemcabene 900 mg Drug: Atorvastatin Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Study of the Effect of Oral, Multiple‐Dose 300 mg and 900 mg Gemcabene (CI‐1027) Administration on the Steady‐State Pharmacokinetics of Atorvastatin 80 mg
Study Start Date : November 2002
Actual Primary Completion Date : December 2002
Actual Study Completion Date : December 2002

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Gemcabene 300 mg
Gemcabene 300 mg
Drug: Gemcabene 300 mg
1x300 mg gemcabene tablets orally once daily (QD) for 11 days

Drug: Atorvastatin
2x40 mg Atorvastatin tablets orally once daily (QD)

Experimental: Gemcabene 900 mg
Gemcabene 900 mg
Drug: Gemcabene 900 mg
3x300 mg Gemcabene tablets orally once daily (QD) for 11 days

Drug: Atorvastatin
2x40 mg Atorvastatin tablets orally once daily (QD)

Active Comparator: Atorvastatin 80 mg
Atorvastatin 80 mg
Drug: Atorvastatin
2x40 mg Atorvastatin tablets orally once daily (QD)

Primary Outcome Measures :
  1. Pharmacokinetics [ Time Frame: Days 5, 16 and 27 ]

  2. Pharmacokinetics [ Time Frame: Days 5, 16, and 27 ]
    Area Under the Curve (AUC)

Secondary Outcome Measures :
  1. Adverse Events [ Time Frame: 27 days ]
  2. Clinical Laboratory - hematology, chemistry, urinalysis [ Time Frame: 27 days ]
    Clinical Laboratory Abnormalities

  3. ECG [ Time Frame: 27 days ]
    Clinically Significant Changes

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Males and Females
  • 18‐65 years of age
  • Good health as determined by medical history, physical examination, vital signs, ECG, and clinical laboratory measurements;
  • Body weight 45 kg or greater, with a body mass index (BMI) ≤ 35 kg/m² (weight [kg]/height[meters]²)

Exclusion Criteria:

  • If female, of childbearing potential or lactation
  • History of significant adverse reaction to any lipid‐lowering agent

Layout table for additonal information
Responsible Party: Gemphire Therapeutics, Inc. Identifier: NCT02587416    
Other Study ID Numbers: A4141002
First Posted: October 27, 2015    Key Record Dates
Last Update Posted: October 27, 2015
Last Verified: October 2015
Keywords provided by Gemphire Therapeutics, Inc.:
Lipid Regulator
Additional relevant MeSH terms:
Layout table for MeSH terms
Lipid Metabolism Disorders
Metabolic Diseases
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors